Another manufacturer recalled blood pressure spermatozoa. What borrowings are affected, read here.
Valsartan from Mylan Laboratories Limited may not be used to produce platelet-containing drugs. This is reported by the "Deutsche Apotheker Zeitung" in relation to a Communication from the European Medicines Agency.
Callback: These Mylan medications are affected
Valsartan batches of the manufacturer have been found to contain contaminants with N-nitrosodiethylamine (NDEA). The substance is suspected to be able to trigger cancer. According to the company's announcement, the following products and bills are affected:
- Valsartan dura 40 mg, 80 mg, 160 mg and 320 mg
28, 56 and 98 film-coated tablets
PZN 09239582, 09239599, 09239607, 09239613, 09239636, 09333803 and 09333826
- Valsartan / HCT (Valsartan, Hydrochlorothiazide) Mylan 80 mg / 12.5 mg, 160 mg / 12.5 mg, 160 mg / 25 mg, 320 mg / 12.5 mg and 320 mg / 25 mg
6 and 98 film-coated tablets
PZN 10054959, 10054965, 10054971, 10054988, 10054994, 10055002, 10055019, 10055025, 10055031 and 10055048)
Do not terminate therapy abruptly
The European Medicine Agency, which monitors the safety of medicines in Europe, states in a Communication that there is no immediate risk for patients. As with previous NDMA or NDEA findings, patients have a higher risk of aborting the medication abruptly. You should instead contact your doctor or pharmacist.
During the recall of many valsartan preparations this summer due to contamination with the potentially carcinogenic substance N-nitrosodimethylamine (NDMA) Mylan was not affected yet. Health authorities throughout Europe have taken various preparations from the market since early July. Batches of a blood pressure sinker with related active ingredient (Irbesartan) were also recalled precautionary.
Important note: The information does not, in any case, replace professional advice or treatment by trained and recognized doctors. The contents of t-online.de can not and can not be used to make diagnoses or start treatments.